ObsEva SA
ObsEva. Nature meets Nurture
Plan-les-ouates, Switzerland
9 employees
Post Ipo Debt
Total: $227.00M
Biotechnology, Health and Wellness +2
General Information
Get notified when ObsEva SA moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track ObsEva SA
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Switzerland Market
Biotechnology
About ObsEva SA
Taxonomy: Clinical-stage biopharmaceutical, Reproductive health, Pregnancy therapeutics, Women's health, Swiss-based company, Preterm labor, Innovative drugs, Female reproductive medicine, Biopharmaceutical industry, Ernest Loumaye, André Chollet, Medicinal and pharmaceutical chemistry, Drug development, Specialty biopharmaceutical company, Clinical development
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | •••••• | 1 | •••• •••• | 08 Aug 2019 |
| Post-IPO Equity | •••••• | 8 |
|
10 Oct 2017 |
| Series B | •••••• | 1 |
|
23 Nov 2015 |
| Series A | •••••• | - | 29 Aug 2013 | |
| Seed Round | •••••• | - | 01 Jan 2013 |
ObsEva SA Alternatives & Competitors
Pioneering novel treatments to enhance pregnancy success and outcomes in reproductive medicine
A midwife for every community
Leading medical research institute recognised internationally for discovery science and translationa...
FAQ About ObsEva SA
Don't just browse. Track.
Signal Tracker monitors ObsEva SA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.